21 Ha’arba’a Street
337 articles with RedHill Biopharma
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 9, 2020.
Opaganib completely inhibited SARS-CoV-2 viral replication as measured after three days incubation in an in vitro model of human bronchial tissue, comparing favorably with remdesivir, the positive control in the study -- Opaganib is uniquely positioned as an orally-administered potential COVID-19 treatment combining potent antiviral and anti-inflammatory mechanisms of actio n, targeting a host cell component and minimizing likelihood of resistance -- Global Phase 2/3 and U.S. Phase 2
A global Phase 2/3 study in up to 270 patients hospitalized with severe COVID-19 pneumonia, and a U.S. Phase 2 study in up to 40 patients, are ongoing with opaganib, a novel, orally-administered, sphingosine kinase-2 (SK2) selective inhibitor with dual anti-inflammatory and anti-viral properties
RedHill Biopharma Announces Positive Recommendation from Independent Committee to Continue U.S. Phase 2 COVID-19 Study, and Approval of COVID-19 Phase 2/3 Study in Italy
A pre-scheduled independent Safety Monitoring Committee (SMC) has recommended that the U.S. Phase 2 COVID-19 study with opaganib continue with no changes; the study is more than 50% enrolled and enrollment is planned to be completed in the coming weeks
Q2/2020 net revenues of approximately $21 million, up from $1.1 million in Q1/2020 and $1.6 million in Q2/2019, an increase of approximately 1,900% and 1,200%, respectively
RedHill Biopharma and Cosmo Pharmaceuticals to Expand Strategic Partnership with Exclusive Licensing Agreement and Manufacturing Agreement for Multiple Products
RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced that it has entered into a binding term sheet with Cosmo Pharmaceuticals N.V. for an exclusive licensing and manufacturing agreement for multiple products.
The global Phase 2/3 study with opaganib is set to enroll up to 270 patients with severe COVID-19 across 40 clinical sites
RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced that it will participate in the following virtual conferences in August
RedHill acquired Movantik® for opioid induced constipation from AstraZeneca in April 2020; Movantik® generated $96 million in 2019
RHB-204 is a potential first-line oral treatment for pulmonary nontuberculous mycobacteria (NTM) infections, a rare disease with no FDA-approved first-line therapy
The global Phase 2/3 study will enroll up to 270 patients with severe COVID-19 across 40 clinical sites; The study has been approved in the UK and Russia and is under review in Italy, Brazil and Mexico
RedHill Biopharma Publishes Positive IBS-D Phase 2 Study Data in The American Journal of Gastroenterology
Publication of the Phase 2 U.S. study data show that RHB-102 (Bekinda ® ) 12mg delivers a clinically meaningful improvement in overall stool consistency response versus placebo in patients with diarrhea-predominant irritable bowel syndrome (IBS-D), meeting the study’s primary endpoint -- In addition, the publication highlights that elevated baseline C-reactive protein (CRP) may be used to identify treatment responders in this complex disease, which lacks reliable predictive markers -- T
Talicia® is the first and only FDA-approved rifabutin-based therapy for H. pylori infection designed as a first-line option to address the high and growing resistance of H. pylori toclarithromycin-based therapies
Phase 2/3 study process initiated in Brazil and Mexico The global Phase 2/3 study with opaganib in patients with severe COVID-19 has already been approved in the UK and Russia Enrollment planned to be initiated this month - 270 subjects to be enrolled in up to 40 clinical sites Potential submission of emergency use applications planned for Q4/2020 Enrollment in parallel U.S. Phase 2 study in severe COVID-19 patients expected to be completed in August TEL-AVIV, Israel and
RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced it is seeking regulatory review by the Securities and Exchange Commission, and intends to approach the Financial Industry Regulatory Authority, Inc., regarding suspicious trading activity including potential naked short selling of the Company’s stock.
Clinical Trial Application approved in Russia for the Phase 2/3 study with opaganib in severe COVID-19 patients following recent approval in the UK and similar submission in Italy -- The Phase 2/3 study aims to enroll 270 subjects in up to 40 clinical sites; enrollment planned to be initiated later this month with potential submission of Emergency Use Authorization application planned for Q4/2020 -- In parallel, the U.S. Phase 2a study with opaganib in patients with severe COVID-19 is ad
RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced that Mr. Gilead Raday, RedHill's Chief Operating Officer, will present the Company’s ongoing Phase 2/3 development programs with opaganib 1 and RHB-107 2 for COVID-19 at the Sachs Digital Novel Coronavirus Investment Forum, taking place July 7-9, 2020.
The Phase 2/3 multi-center, randomized, double-blind, parallel-arm, placebo-controlled study with opaganib aims to enroll 270 severe COVID-19 patients in up to 40 clinical sites across the UK, Italy, Russia and additional countries -- In parallel, a U.S. study with opaganib in up to 40 severe COVID-19 patients has been initiated at leading medical centers TEL-AVIV, Israel and RALEIGH, N.C., June 29, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or
Publication of Data from Severe COVID-19 Patients Shows Substantial Benefit to Patients Treated with RedHill’s Opaganib Compared to Matched Case-Control Group
Analysis of treatment outcomes in five severe COVID-19 patients showed substantial benefit to patients treated with opaganib under compassionate use in both clinical outcomes and inflammatory markers as compared to a matched case-control group from the same hospital
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 24, 2020.